Prandin Side Effects
Generic Name: repaglinide
Note: This page contains side effects data for the generic drug repaglinide. It is possible that some of the dosage forms included below may not apply to the brand name Prandin.
It is possible that some side effects of Prandin may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to repaglinide: oral tablet
As well as its needed effects, repaglinide (the active ingredient contained in Prandin) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking repaglinide, check with your doctor immediately:More common
- Convulsions (seizures)
If any of the following side effects occur while taking repaglinide, check with your doctor or nurse as soon as possible:More common
- low blood sugar, including anxious feeling, behavior change similar to being drunk, blurred vision, cold sweats, confusion, cool pale skin, difficulty in thinking, drowsiness, excessive hunger, fast heartbeat, headache, nausea, nervousness, nightmares, restless sleep, shakiness, slurred speech, or unusual tiredness or weakness
- pain in the chest
- runny or stuffy nose
- shortness of breath
- sinus congestion with pain
- sore throat
- Bloody or cloudy urine
- burning, painful, or difficult urination
- chest pain
- frequent urge to urinate
- problems with teeth
- skin rash, itching, or hives
- tearing of eyes
- tightness in chest
- trouble in breathing
- Black, tarry stools
- blood in stools
- fast or irregular heartbeat
- lower back or side pain
- pinpoint red spots on skin
- unusual bleeding or bruising
Some repaglinide side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Back pain
- joint pain
- feeling of burning, numbness, tightness, tingling, warmth, or heat
For Healthcare Professionals
Applies to repaglinide: oral tablet
Repaglinide has been usually well tolerated. Over one year, 13% of patients treated with repaglinide (the active ingredient contained in Prandin) in clinical trials discontinued due to adverse events.
Metabolic side effects have included hypoglycemia, an extension of repaglinide (the active ingredient contained in Prandin) s pharmacologic effects. Hypoglycemia occurred in 16% of patients treated with repaglinide. Patients with liver disease may be at an increased risk of hypoglycemia due to diminished gluconeogenic capacity.
Cardiovascular side effects have included angina and chest pain which were reported in 1.8% of patients treated over one year. The overall incidence of other cardiovascular events including hypertension, abnormal EKG, myocardial infarction, arrhythmias, and palpitations was less than 1%.
The incidence of serious cardiovascular adverse events, including ischemia, was higher for repaglinide (the active ingredient contained in Prandin) (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In one year controlled trials, repaglinide was not associated with increased mortality rates compared to rates observed with other oral hypoglycemic agents.
Hypersensitivity side effects during clinical trials involving 2,931 patients include one patient who experienced an anaphylactoid reaction.
Gastrointestinal side effects have included nausea, vomiting, diarrhea, constipation, and dyspepsia which occurred in up to 5% of patients in clinical trials.
Nervous system side effects have included headache which was reported with an incidence of 9% to 11% in patients taking repaglinide (the active ingredient contained in Prandin) compared to 10% in placebo treated patients. Paresthesia was also reported with an incidence of 2% to 3%.
Musculoskeletal side effects have included back pain and arthralgia which were reported in 5% and 6% of patients, respectively.
Respiratory side effects have included upper respiratory infection, sinusitis, rhinitis, and bronchitis which were reported in 2% to 16% of patients. These frequencies were similar to those reported for placebo-treated and sulfonylurea-treated patients.
Postmarketing experience has included reports of severe hepatic dysfunction including jaundice and hepatitis.
Hepatic side effects have included elevated liver enzymes which were reported in less than 1% of patients in clinical trials. Additionally, there have been case reports of acute hepatotoxicity and cholestatic hepatitis.
Hematologic side effects have included thrombocytopenia and leukopenia which were reported in less than 1% of patients.
Ocular side effects have included blurred vision and visual disturbances, especially at the initiation of treatment.
More about Prandin (repaglinide)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.